Guess which ASX 300 healthcare stock just tanked 20%

FY23 was a year of transformation for this company.

| More on:
A female scientist sits at her desk looking stressed out while working in an AnteoTech lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Mayne Pharma Group Ltd (ASX: MYX) share price is down 20% after the company released its unaudited FY23 full-year results.

The ASX 300 healthcare stock opened at $4.68, down 1.5% on Thursday. It fell to an intraday low of $3.71 in morning trading.

The Mayne Pharma share price is currently $3.81, down 19.79% for the day. Let's check out the results.

Mayne Pharma share price plummets on 44% earnings drop

Here are the key points:

  • Reported revenue of $183.6 million, up 17% on FY22
  • Reported gross profit of $83.5 million, up 17% on FY22
  • Reported earnings before interest, taxes, depreciation, and amortisation (EBITDA) of a loss of $102 million vs. $9 million EBITDA in FY22
  • Reported net loss after tax of $317.4 million, down 44% on FY22
  • $172.6 million net cash position vs. net debt of $317 million at the end of FY22
  • No final dividend.

What else happened in FY23?

Mayne Pharma's branded products revenue of $61.9 million represented an impressive 484% lift on FY22.

Portfolio products revenue of $57 million was down 38% on FY22. International revenue increased 19% to $64.7 million, largely due to increased contract manufacturing in 2H FY23.

A primary focus in FY23 was transforming Mayne Pharma into a specialty pharmaceutical company. It wants to attain a leading position in women's health and dermatology and return to profitability.

A number of milestones occurred during FY23.

In August 2022, Mayne Pharma announced the sale of its Metrics Contract Services business for US$475 million.

In October, the company announced a fully franked special dividend of 2.72 cents per share. It also announced a pro-rata return of capital of 3.8 cents per share, but this was cancelled in February.

Investors thought this was a smart decision, with the Mayne Pharma share price lifting 5.4% on the news.

In December, Maybe Pharma acquired the exclusive US license to a portfolio of on-market women's health products (ANNOVERA, IMVEXXY and BIJUVA) and pre-natal vitamins. The deal cost US$140 million and included potential sales-based milestone cash payments and sales-based royalties.

It appeared investors weren't convinced of the value here. The ASX 300 healthcare stock dropped 12.5% on the day of the announcement.

In February, Mayne Pharma announced the US$90 million sale of its US retail generics portfolio business.

In May, the Mayne Pharma share price fell 9% on news of a share buyback of up to 10% of issued capital.

The company recorded a cash outflow from operating activities of $42.7 million in FY23. It notes that there was a "significant improvement in business performance" in 2H FY23.

During the second half, there was a positive operating cash flow of $14.1 million.

Created with Highcharts 11.4.3Mayne Pharma Group PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.com.au

What did management say?

Mayne Pharma CEO Shawn Patrick O'Brien, who joined the company in October 2022, said:

Fiscal year 2023 has been one of significant change at Mayne Pharma. We have reshaped the business to focus on our core areas of Women's Health, Dermatology and our International operations.

Both our BPD/Women's Health and International segments showed year-over-year revenue growth, and, in the second half, we delivered improved operational and financial performance across all three segments.

With accelerating sales momentum and ongoing cost discipline, Mayne Pharma enters FY24 well positioned for sustainable long-term growth.

What's next for Mayne Pharma?

Mayne Pharma says it expects to return to positive EBITDA and cash generation in FY24.

Drilling down in its women's health division, the company will work to complete the integration of the news in-licensed women's health assets.

In its dermatology business, the company is planning capital-light, accretive business arrangements, including further developing its channel strategy and expanding partnerships to capture market share.

In its international business, Mayne Pharma will pursue targeted investment and new manufacturing revenue streams.

Mayne Pharma share price snapshot

The Mayne Pharma share price is down 9.75% in the year to date. The ASX 300 healthcare stock has lost 37% of its value over the past 12 months.

By comparison, the S&P/ASX 200 Health Care Index (ASX: XHJ) has fallen 6.3% over the same period.

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Earnings Results

A woman looks up at a plane flying in the sky with arms outstretched as the Flight Centre share price surges
Earnings Results

Web Travel share price rockets 13% on market leading full-year growth

Investors are sending Web Travel shares soaring today. Here’s why.

Read more »

Happy shopper at a clothes shop.
Earnings Results

Why did Myer shares just rocket 9%?

Investors are piling into Myer shares on Friday. But why?

Read more »

A woman looks up at a plane flying in the sky with arms outstretched as the Flight Centre share price surges
Earnings Results

Up 78% since April, why is the Webjet share price taking off again today?

Webjet shares have soared 78% since 4 April and are lifting off again today. But why?

Read more »

a woman holds her hands to her temples as she sits in front of a computer screen with a concerned look on her face.
Industrials Shares

Guess which ASX 200 stock is crashing 24% on results day

Investors were not impressed with this result. But why?

Read more »

A man in full American NFL playing kit crouches over with his arms across his chest in a defensive stance against a dark background.
Technology Shares

ASX 300 tech stock charges 7% higher to record high on stellar results

This tech stock delivered another impressive result this morning.

Read more »

a group of people sit around a computer in an office environment.
Earnings Results

Guess which ASX 200 tech stock is rocketing 12% on record results

Another half, another record result from this high-quality company.

Read more »

A young man sitting at an outside table uses a card to pay for his online shopping.
Consumer Staples & Discretionary Shares

Why is the Kogan share price crashing 12%?

Profits are down at this ecommerce company during the second half.

Read more »

Frustrated stock trader screaming while looking at mobile phone, symbolising a falling share price.
Resources Shares

Guess which ASX 200 mining stock is sinking 7% following its quarterly update

Let's see how this miner performed during the third quarter.

Read more »